Rapport Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
99 HIGH STREET, BOSTON, MA, 02110
Mailing Address
99 HIGH STREET, BOSTON, MA, 02110
Phone
857-321-8020
Fiscal Year End
1231
EIN
880724208
Financial Overview
FY2025
$484.65M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 31, 2026 | View on SEC |
| 4 Insider stock transaction report | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 10, 2026 | View on SEC |
| 10-K Annual financial report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
Annual Reports
10-K
March 10, 2026
- Proprietary RAP technology platform for precision medicines targeting CNS disorders, aiming for improved effectiveness and fewer side effects.
- Lead product candidate RAP-201 successfully completed Phase 1 trial with favorable safety and preliminary efficacy, with Phase 2 initiating mid-2024.
Insider Trading
STRONG SELL
4 insiders
26 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.